References 1. Adami HO, Hansen J, Jung B, Rimsten A. Characteristics of familial breast cancer in Sweden: absence of relation to age and unilateral and bilateral disease. Cancer 1981, 48, 1688-95. 2. Lubin JH, Burns PE, Blot WJ, et al. Risk factors for breast cancer in women in North Alberta, Canada, as related to age at diagnosis. J Natl Cancer Inst 1982, 68, 211-7. 3. Bain C, Speizer FE, Rosner B, Belanger C, Hennekens CH. Family history of breast cancer as a risk indicator for the disease. Am J Epidemiol 1980, 111, 301-7. 4. Anderson DE. Some characteristics of familial breast cancer. Cancer 1971, 28, 15004. 5. Anderson DE. Genetic study of breast cancer: identification of a high risk group. Cancer 1974, 34, 1090-7. 6. Anderson DE. Breast cancer in families. Cancer 1977, 40, 1855-60. 7. Lynch HT, Krush AJ, Lemon HM, Kaplan AR Condit PT, Bottomley RH. Tumour variation in families with breast cancer. JAMA 1972, 222, 1631-5. 8. Williams WR, Anderson DE. Genetic epidemiology of breast cancer: segregation analysis of 200 Danish pedigrees. Genet Epidemiol 1984, 1, 7-20. 9. Newman B, Austin MA, Lee M, King M-C. Inheritance of breast cancer: evidence of autosomal dominant transmission in high risk families. Proc Natl Acad Sci USA 1988, 85, 3044-8. 10. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991, 48, 232-42. 11. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset breast cancer to chromosome 17q21. Science 1990, 250, 1684-9. 12. Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17q12-23. Lancet 1991, 338, 82-3. 13. Feunteun J, Narod SA, Lynch HT, et al. A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. Am J Hum Genet 1993, 52, 736-42. 14. Miki Y, Swenson J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266, 66-71. 15. Wooster R, Neuhausen SL, Mangion J, et al. Localisation of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265, 2088-91. 16. Schutte M, Rozenblum E, Moskaluk CA, et al. An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12. Cancer Res 1995, 55, 4570-4. 17. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378, 789-92. 18. Narod SA, Ford D, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995, 56, 254-64. 19. Narod SA, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 1995, 57, 958-60. 20. Easton DF, Bishop DT, Ford D, Crockford GP, Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993, 52, 678-701. 21. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62, 676-89. 22. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995, 57, 145762. 23. Whittemore A, Gong G, Itnye J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population case-control studies of ovarian cancer. Am J Hum Genet 1997, 60, 496-504. 24. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999, 91, 943-9. 25. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1mutation carriers. Am J Hum Genet 1995, 56, 265-71. 26. Struewing J, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336, 1401-8. 27. Fodor FH, Weston A, Bleiweiss IJ, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998, 63, 45-51. 28. Dorum A, Heimdal H, Hovig E, Inganas M, Moller P. Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer. Am J Hum Genet 1999, 65, 671-9. 29. Hopper JL, Southey MC, Dite GS, et al. Population – based estimate of the average age – specific cumulative risk of breast cancer for a defined set of protein – truncating mutations in BRCA1 and BRCA2. Cancer Epidemio Biomarkers Prev 1999, 8, 741-7. 30. Friedman LS, Szabo CI, Ostermeyer EA, et al. Novel inherited mutations and variable expressibility of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995, 57, 1284-97. 31. Devilee P. BRCA1 and BRCA2 testing: weighing the demand against the benefits [editorial]. Am J Hum Genet 1999, 64, 943-8. 32. Foulkes WD. BRCA1 and BRCA2: penetrating the clinical arena [commentary]. Lancet 1998, 352, 1325-6. 33. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997, 61, 120-8. 34. Shattuck-Eidens D, McClure M, Simard J, et al. Collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 1995, 273, 53541. 35. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993, 2, 425-34. 36. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993, 329, 1982-7. 37. Simard J, Tonin P, Durocher F, et al. Common origin of the BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1997, 8, 392-98. 38. Gao Q, Neuhausen S, Cummings S, Luce M, Olopade OI. Recurrent germline BRCA1 mutations in extended African American Families with early-onset Breast Cancer. Am J Hum Genet 1997, 60, 1233-6. 39. Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA, Simard J. Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J Med Genet 1996, 33, 814-9. 40. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. JAMA 1997, 278, 1242-50. 41. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutation in chromosome 13q-linked kindreds. Nat Genet 1996, 12, 333-7. 42. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998, 16, 2417-25. 43. Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BAJ. Frequently occurring germline mutation of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet 1997, 60, 1239-42. 44. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagao M. Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res 1995, 55, 3521-4. 45. Lavy-Lehad E, Catane R, Eisenberg S, et al. Recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997, 60, 1059-67. 46. Caligo MA, Ghimenti C, Cipollini G, et al. BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene. 1996, 13, 1483-8. 47. De Benedetti V, Radice P, Mondini P, et al. Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by the protein truncation test. Oncogene 1996, 13, 1353-57. 48. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997, 60, 107984. 49. Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996, 13, 117-9. 50. Struewing J, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately percent in Ashkenazi Jewish individuals. Nat Genet 1995, 11, 198-200. 51. Takahashi H, Behnakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancer. Cancer Res 1995, 55, 2998-3002. 52. Tonin P, Serova O, Lenoir H, et al. BRCA1 mutation in Ashkenazi Jewish women. Am J Hum Genet 1995, 57, 189. 53. Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG mutation kindreds. Am J Hum Genet 1996, 58, 116676. 54. Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected with breast cancer. Nat Genet 1996, 13, 126-8. 55. Oddoux C, Struewing J, Clayton C et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jews is approximately percent. Nat Genet 1996, 14, 188-90. 56. Roa BB, Boyd AA, Richards KV, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14, 1857. 57. Wagner TMU, Moslinger RA, Muhr D, et al. BRCA1 - related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer 1998, 77, 354-360. 58. Tonin PN, Mes-Masson A-M, Narod SA, Ghadirian P, Provencher D. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet 1999, 55, 318-24. 59. Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder effects in Dutch breast cancer patients. Nat Genet 1997, 7, 341-5. 60. Anderson TI, Borresen A-L, Moller P. A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am J Hum Genet 1996, 59, 486-7. 61. Dorum A, Moller P, Kamsteeg EJ, et al. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. Am J Hum Genet 1997, 33, 2390-2. 62. Gorski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast – ovarian cancer. Am J Hum Genet 2000, 66, 1963-8. 63. Liede A, Cohen B, Black DM, et al. Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer 2000, 82, 705-711. 64. Ford D, Easton DF, Bishop DF Narod SF, Goldgar DE and the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994, 343, 692-5. 65. Lin KM, Ternent CA, Adams DR, et al. Colorectal cancer in hereditary breast cancer kindreds. Dis Colon Rectum 1999, 42, 1041-5. 66. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 1999, 35, 1248-57. 67. Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, Ostrander EA. Germline BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 1996, 58, 881-5. 68. Lehrer S, Fodor F, Stock RG, et al. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998, 78, 771-3. 69. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldson H. Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer. Br Med J 1992, 305, 855-7. 70. Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-speicific breast cancer families. Nat Genet 1996, 13, 120-122. 71. Breast Cancer Linkage Consortium. Cancer risk in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91, 1310-6. 72. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia. Am J Pathol 2000, 156, 1767-71. 73. Goggins M, Schuute M, Lu J, et al. Germline BRCA2 gene mutations in patients in apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56, 5360-4. 74. Hruban RH, Peterson GM, Goggins M, et al. Familial pancreatic cancer. Ann Oncol 1999, 10(Suppl 4), S69-73. 75. Lal G, Liu G, Schmocker B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ - line p16, BRCA1 and BRCA2 mutations. Cancer Res 2000, 60, 409-16. 76. Nastiuk KL, Mansukhani M, Terry MB, et al. Common mutations in BRCA1 and BRCA2 not contribute to early prostate cancer in Jewish men. Prostate. 1999, 40, 172-7. 77. Wilkens EP, Freije D, Xu J, et al. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 1999, 39, 280-4. 78. Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 2000, 60, 1371-5. 79. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994, 8, 399-404. 80. Vehmanen P, Friendman LS, Eerola H, et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997, 13, 2309-15. 81. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M. Germline mutations of BRCA1 gene in breast and ovarian cancers provide evidence for a genotype-phenotype correlation. Nat Genet 1995, 11, 428-33. 82. Serova O, Montagna M, Torchard D, et al. A high incidence of BRCA1 mutations in breast-ovarian cancer families. Am J Hum Genet 1996, 58, 42-51. 83. Gayther SA, Mangion J, Russel P, et al. Variation of risks of breast and ovarian cancer associated with different germ line mutations of the BRCA2 gene. Nat Genet 1997, 15, 103-5. 84. Neuhausen SL, Godwin AK, Gershoni-Baruch R, et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study Am J Hum Genet 1998, 62, 1381-8. 85. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994, 226, 120-2. 86. Lancaster JM, Wooster R, Mangion J, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13, 238-40. 87. Jacquemier J, Eisinger F, Birnbaum D, Sobol H. Histoprognostic grade in BRCA1associated breast cancer [letter]. Lancet 1995, 345, 1503. 88. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 1996, 77, 697-709. 89. Eisinger F, Soppa-Lyonnet, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996, 56, 471-4. 10 115. Robson M, Gilewski T, Haas B, et al. BRCA - associated breast cancer in young women. J Clin Oncol 1998, 16, 1642-9. 116. Swift M, Morrell D, Cromartie E, Chamberlain AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia on the United States. Am J Hum Genet 1986, 39, 573-83. 117. Swift M, Reitnauer PJ, Morrell D, Chase C. Breast and other cancers in families with ataxia-telangiectasia. New Engl J Med 1987, 316, 1289-94. 118. Borresen AL, Anderson TI, Tretli S, Heiberg A, Moller P. Breast cancer and other cancers in Nowegian families with ataxia-telangiectasia. Genes Chromosomes Cancer 1990, 2, 339-403. 119. Pippard EC, Hall AJ, Barker DJ, Bridges BA. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res 1988, 48, 2929-32. 120. Easton DF. Cancer risks in AT heterozygotes. Int J Radiat Biol Phys. 1994, 66(6 Suppl), S177-82. 121. Easton DF. The inherited component of cancer. Br Med Bull 1994, 50, 226. 122. Gatti RA, Lange E, Rotman G, et al. Genetic haplotyping of ataxia-telangiectasia families localises the major gene to an ≈850 kb region on chromosome 11q23.1. Intl J Radiat Biol 1994, 66, S57-62. 123. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 1995, 238, 1749-53. 14 124. Athma P, Rappaport R, Swift M. Molecular genotyping shows that at heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996, 92, 130-134. 125. Inskip HM, Kinlen LJ, Taylor AMR, Woods CG, Arlett CF. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 1999, 79, 1304-7. 126. Stankovic T, Kidd AMJ, Sutcliffe A, et al. ATM mutations and phenotypes in ataxia-telangiectasia famlies in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer. Am J Hum Genet 1998, 62, 334-45. 127. Janin N Andrieu N, Ossian K, et al. Breast cancer in ataxia-telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 1999, 80, 10425. 128. Fitzgerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations not contribute to early onset of breast cancer. Nat Genet 1997, 15, 307 – 310. 129. Vorenchovsky I, Rasio D, Luo L, et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumours reveals no evidence of mutation. Cancer Res 1996, 15, 2726-32. 130. Vorechovsky I, Luo l, Lindbolm A, et al. ATM mutations in cancer families. Cancer Res 1996, 56, 4130-3. 131. Meyn SM. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 1999, 55, 289-304. 15 132. Broeks A, Urbanus JHM, Floore AN, et al. ATM - heterozygous germline mutations contribute to breast cancer – susceptibility. Am J Hum Genet 2000, 66, 494-500 133. Bishop DT, Hopper H. AT-tributable risks? [commentary] Nat Genet 1997, 15, 226. 134. Li F, Fraumeni JF. Soft tissue sarcomas, breast cancer and other neoplasms: A familial syndrome? Ann Intern Med 1969, 71, 747-51. 135. Li FP, Fraumeni JF. Prospective study of a family cancer syndrome. JAMA 1982, 247, 2692-4. 136. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 1987, 79, 1213-20. 137. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990, 250, 12338. 138. Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 mutations in breast cancer. Cancer Res 1992, 52, 2984-6. 139. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. P53 mutations in breast cancer. Cancer Res 1992, 52, 5291-8. 140. Lloyd KM II, Dennis M. Cowden’s disease: a possible new symptom complex with multiple system involvement. Ann Intern Med 1963, 58, 136-42. 141. Weary PE, Gorlin RJ, Gentry WC, Comer Jean, Greer KE. Multiple hamartoma syndrome (Cowden’s disease). Arch Dermatol 1972, 106, 682-90. 16 142. Weinstock JV, Kawanishi H. Gastrointestinal polyposis with orocutaneous harmatomas (Cowden’s disease). Gastroenterology 1978, 74, 890-5. 143. Starink TM. Cowden’s disease (multiple harmatoma and neoplasia syndrome). J Am Acad Dermatol 1983, 8, 686-96. 144. Brownstein MH, Wolf M, Bikowski JB. Cowden’s disease: a cutaneous marker of breast cancer. Cancer 1978, 41, 2393-8. 145. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275, 1943-7. 146. Li DM, Sun H. TEP1, encoded by a candidate tumour suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor. Cancer Res 1997, 57, 2124-9. 147. Longy M, Coulon V, Duboue B, et al. Mutations at PTEN in patients with Bannayan – Riley – Ruvalcaba phenotype. J Med Genet 1998, 35, 886-9. 148. Feilotter HE, Coulon V, McVeigh JL, et al. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 1999, 79, 718-23. 149. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostatic cancer. Cancer Res 1997, 57, 4997-5000. 150. Risinger J Isaac, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997, 57, 4736-8. 151. Guldberg P, Thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997, 57, 3660-3. 17 152. De Vivo I, Gertig DM, Nagase S, et al. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J Med Genet 2000, 37, 336-41. 153. German J. Bloom syndrome: a Mendellian prototype of somatic mutational disease. Medicine 1993, 72, 393-406. 154. Deng C-X, Brodie SG. Roles of BRCA1 and its interacting proteins [review]. Bioessays 2000, 22, 728-37. 155. Deng C-X, Scott F. Role of the tumour suppressor gene BRCA1 in genetic stability and mammary gland tumour formation. Oncogene 2000, 19, 1059-64. 156. Wilson CA Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high - grade, non - inherited breast carcinomas. Nat Genet 1999, 21, 23640. 157. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995, 9, 444-50. 158. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Ca Res 1997, 57, 3347-50. 159. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997, 386, 761- 3. 160. Xu X, Qiao W, Linke SP, et al. Genetic interactions between tumor suppressors BRCA1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001, 28, 26671 18 161. Yang Q, Khoury MJ, Rodriguez C, Calle EE, Tatham LM, Dana Falnders W. Family history score as a predictor of breast cancer mortality: Prospective data from the Cancer Prevention Study II, United States, 1982-1991. Am J Epidemiol 1998, 147, 652-9. 162. Hoskins KF, Stopfer Jean, Calzone KA, et al. Assessment and counselling for women with a family history of breast cancer: a guide for clinicians. JAMA 1995, 273, 577-85. 163. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV Ostrander EA. BRCA1 mutations and breast cancer in the general population. JAMA 1998, 279, 92229. 164. Lynch H, Lynch J, Conway T, Severin M. Psychological aspects of monitoring high-risk women for breast cancer. Cancer 1994, 74, 1184-92. 165. Biesecker BB, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993, 269, 1970-4. 166. Lerman C, Daly M, Masny M, Balshem A. Attitudes about genetic testing for breast -ovarian cancer susceptibility. J Clin Oncol 1994;12:843-50. 167. Lerman C, Bisecker B, Benkendorf JL, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 1997, 89, 148-57 168. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996, 275, 1885-92 19 169. McKinnon WC, Baty BJ, Bennett RL, et al. Predisposition gene testing for late – onset disorders in adults: a position paper of the National Society of Genetic Counsellors. JAMA 1997, 278, 1217-20. 170. Geller G, Botkin JR, Green MJ, et al. Genetic testing for susceptibility to adult – onset cancer: the process and content of informed consent. JAMA 1997, 277, 146774. 171. The American Society of Human Genetics Social Issues Subcommitee on Familial Disclosure. Professional disclosure of familial genetic information. Am J Hum Genet 1998, 62, 474-83. 172. America Society of Clinical Oncology. Statement of the American Society of Clinical Onclogy: Genetic testing for cancer susceptibility. J Clin Oncol 1996, 14, 1730-6. 173. Eisinger F, Alby N, Bremond A, et al. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 1998, 9, 939-50. 174. Pharoah PD, Stratton JF, Mackay J. Screening for breast and ovarian cancer: the relevance of family history. Br Med Bull 1998, 54, 823-38. 175. Berry DA, Giovanni P, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of the breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997, 89, 227-38. 176. Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998, 62, 145-59. 20 177. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population based sample of young women with breast cancer. N Engl J Med 1996, 334, 137-42. 178. Southey MC, Tesoriero AA, Anderson CR, et al. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer 1999, 79, 34-9. 179. Liede1 A Narod SA. Hereditary Breast and Ovarian Cancer in Asia: Genetic Epidemiology of BRCA1 and BRCA2. Hum Mutat 2002, 20, 413–424. 180. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T and Nagao M. Germline mutations of BRCA1 in Japanese breast cancer families. Cancer Res 1995, 55, 3521-24. 181. De Leon Matsuda ML, Liede A, Kwan E, , et al. BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 2002, 98, 596-603. 182. Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, , et al. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated earlyonset breast and ovarian cancer. Hum Mutat 2002, 20, 230. 183. Tang NLS, Pang CP, Yeo W, et al. Prevalence of mutations in BRCA1 gene among Chinese patients with breast cancer. J Natl Cancer Inst 1999, 91, 882-85 184. Sng HJ, Chang J, Feroze F, et al. The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer 2000, 82, 538-42. 21 185. Ho GH, Phang BH, Ng IS, Law HY, Soo KC, Ng EH. Novel germline BRCA1 mutations detected in women in Singapore who developed breast carcinoma before the age of 36 years. Cancer 2000, 89, 811-6. 186. Seow A, Duffy SW, McGee MA, Lee HP. Breast cancer in Singapore: trends in incidence 1968-1992. Int J Epidemiol 1996, 25, 40-5. 187. Kollias J, Sibbering DM, Blamey RW, et al. Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer 1998, 34, 878-83. 188. Skolnick M. The Utah geneological database: a resource for genetic epidemiology. In Cairns J, Lyon JL, Skolnick M eds. Banbury Report No. 4: cancer incidence in defined populations. Cold Spring Harbour NY, Cold Spring Harbour Laboratory, 1980, 285-97. 189. Goldgar DE, Easton DR, Cannon - Albright LA, Skolnick MH. Systematic population - based assessment of cancer risk in first - degree relatives of cancer probands. J Natl Cancer Inst 1994, 86, 1600-8. 190. Claus EB, Risch N, Thompson WD. Age of onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990, 131, 961-72 191. Goldgar DE, Stratton MR, Eeles RA. Familial breast cancer. In Eeles RA, Ponder BAJ, Easton DF, Horwich A, eds. Genetic predisposition to cancer. London,: Chapman & Hall, 1996, 227-38. 192. Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: a systemic review and meta-analysis. Int J Cancer 1997, 71, 800-9. 22 193. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early- onset breast cancer: implications for risk prediction. Cancer 1994, 73, 643-51. 194. Gail MH, Brinton LA, Byar DP, et al. Projecting individualised probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81, 1879-86. 195. Benichou J. A computer program for estimating individualized probabilities of breast cancer . Comput Biomed Res 1993, 26, 373-82. 196. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualiszed risk of breast cancer. J Clin Oncol 1996, 14, 103-10. 197. Gail MH, Benichou J. Assessing the risk of breast cancer in individuals. In DeVita VT Jr, Hellerman S, Rosenberg SA, eds. Cancer Prevention (Philadelphia, Lippincort), 1992, 1–15. 198. Vogel V, Mondy M, Halabi S, et al. Validation of Gail’s breast cancer risk model. Proc ASCO 1993, 12, 167. 199. Spiegelman D, Colditz Ga, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994, 86, 600-7. 200. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994, 86, 620-5. 201. Costantino JP, Gail MH, Pee D, et al. Validation studies for models predicting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999, 91, 1541-7. 23 202. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992, 20, 479-89. 203. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathological study with 10 year follow-up. Cancer 1977, 40, 13651385. 204. Grompe M. The rapid detection of unknown mutations in nucleic acids. Nat Genet 1993, 5, 111-7. 205. Greenman J, Mohammed S, Ellis D, et al. Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer. Genes Chrom Cancer 1998, 21, 244-9. 206. Orita M, Iwahana H, Kanazawa H, Hayashi K Sekiya T. Detection of polynorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989, 86, 2766-70. 207. Michaud J, Brody LC, Steel G, et al. Strand - separating conformational polymorphism analysis: efficacy of detection of point mutations in the human ornithine delta-aminotransferase gene. Genomics 1992, 13, 389-94. 208. White MB, Carvalho M, Derse D, O’Brien SJ, Dean M. Detecting single base substitutions as heteroduplex polymorphisms. Genomics 1992, 12, 301-6. 209. Sambrook J, Fritsch EF and Maniatis T. Isolation of high molecular weight DNA from mammalian cells. New York, Cold Spring Harbor Laboratory Press, 1989. 24 210. Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BA. Rapid detection of regionally clustered germline mutations by multiplex heteroduplex analysis. Am J Hum Genet 1996, 58, 451-6. 211. Roest PAM, Roberts RG, Sugino S, Van Ommen GJB, Dunnen JT. Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum Mole Genet 1993, 2, 1719-21. 212. Hogervorst FBL, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995, 10, 208-12. 213. Plummer SJ, Anton-Culver H, Webster L, et al. Detection of BRCA1 mutations by the protein truncation test. Hum Mol Genet 1995, 4, 1989-93. 214. Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Page`s S, LynchHT, Lenoir GM, Mazoyer S. Screening for germline rearrangements and regulatory mutations in BRCA1 led the identification of four new deletions. Cancer Res 1999, 59, 455–461. 215. The Exon 13 Duplication Screening Group. The Exon 13 duplication in the BRCA1gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 2000, 67, 207-12. 216. Unger MA, Nathanson KL, Calzone K, et al. Screening for genomic rearrangement in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation – sensitive gel electrophoresis or sequencing. Am J Hum Genet 2000, 67, 841-50 217. Payne SR, Newman B, King M-C. Complex germline rearrangement of BRCA1 associated with breast and ovarian cancer. Genes Chrom Cancer 2000, 29, 58-62. 25 218. Robledo M, Osorio A, Sentis C, Albertos J, Erstevez L, Benitez J. The 12 base pair duplication/insertion alteration could be a regulatory mutation. J Med Genet 1997, 34, 592-3. 219. Takahashi H, Behnakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancer. Cancer Res 1995, 55, 2998-3002. 220. Laskie Ostrow K, DiCioccio RA, McGuire V, Whittemore AS. A BRCA1 variant, IVS23+1G→A, causes abnormal RNA splicing by deleting exon 23. Cancer Genet Cytogenet 2001, 127, 188-90 221. Liu X, Barker DF. Evidence for effective suppression of recombination in the chromosome 17q21 segment spanning RNU2-BRCA1. Am J Hum Genet 1999. 64, 1427-39. 222. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77, 2318-24. 223. Pederson L, Holck S, Schiodt T, Zedeler K, Mouridsen HT. Inter - and intraobserver variability in the histopathological diagnosis of medullary carcinoma of the breast, and its prognostic implications. Br Cancer Res Treat 1989, 14, 97-9. 224. Pederson L, Zedeler K, Holck S, Shiodt T, Mouridsen HT. Medullary carcinoma of the breast, proposal for a simplified histopathological definition. Br J Cancer 1991, 63, 591-5. 225. Rigaud C, Theobald S, Noel P, et al. Medullary cancer of the breast: a multicentre study of its diagnostic consistency. Arch Pathol Lab Med 1993, 117, 1005-8. 26 226. Pederson L, Holck S, Schiodt T, Zedeler K, Mouridsen HT. Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. Eur J Cancer 1994, 30A, 1792-7. 227. Eisinger F, Soppa-Lyonnet, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996, 56, 471-4. 228. Kollias J, Elston CW, Ellis IO, Robertson JFR, Blamey RW. Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer 1997, 75, 1318-23. 229. Rosen PP, Lesser ML, Senie MA, Kinne DWQ. Epidemiology of breast carcinoma III: relationship of family history to tumour type. Cancer 1982, 50, 1719. 230. Puget N, Torchard D, Serova-Sininikova OM, et al. A 1-kb Alu-mediated germ- line deletion removing BRCA1 exon 17. Cancer Res 1997, 57, 828-31. 231. Montagna M, Santcatterina M, Torri A, et al. Identification of a kb Alu – mediated BRCA1 gene rearrangement in two breast - ovarian cancer families. Oncogene 1999, 18, 4160-5. 232. Rohlfs EM, Puget N, Graham ML, et al. An Alu – mediated 7.1 kb deletion of BRCA1 exons and in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chrom Cancer 2000, 28, 300-7. 233. Barkardottir RB, Sarantaus L, Arason A, et al. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. Eur J Hum Genet. 2001, 9, 7739. 27 234. Neuhausen SL. Founder populations and their uses for breast cancer genetics. Breast Cancer Res 2000, 2, 77–81. 235. Moller P, Heimdal K, Apold J, et al. Norwegian Inherited Ovarian Cancer Group. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001, 37, 2428-34. 236. Liede A, Imtiaz A, Malik A, et al. Contribution of BRCA1 and BRCA2 Mutations to Breast and Ovarian Cancer in Pakistan Am. J. Hum. Genet. 2002, 71, 595–606. 237. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA 1997, 277, 997-1003. 238. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002, 20, 1260-1268. 239. Smith TJ, Davidson NE, Schapira DV, et al for the American Society of Clinical Oncology Breast Cancer Surveillance Expert Panel. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999, 17, 1080-2. 240. Lalloo F, Boggis CR, Evans DG, Shenton A, Threlfall AG, Howell A. Screening by mammography, women with a family history of breast cancer. Eur J Cancer. 1998, 34, 937-40. 241. Tilanus - Linthorst MMA, Bartels CCM, Obdejin AIM, Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 2000, 36, 514-9. 28 242. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001, 19, 3524-3531. 243. Hartmann LC, Schaid DJ, Woods J, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl J Med 1999, 340, 77-84. 244. Antoniou A, Pharoah PDP, Narod S, et al. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. 2003, 72, 1117– 1130. 29 [...]... the BRCA1 gene in ovarian cancer Cancer Res 1995, 55, 29 98-30 02 220 Laskie Ostrow K, DiCioccio RA, McGuire V, Whittemore AS A BRCA1 variant, IVS23+1G→A, causes abnormal RNA splicing by deleting exon 23 Cancer Genet Cytogenet 20 01, 127 , 188-90 22 1 Liu X, Barker DF Evidence for effective suppression of recombination in the chromosome 17q21 segment spanning RNU2 -BRCA1 Am J Hum Genet 1999 64, 1 427 -39 22 2... in Asia: Genetic Epidemiology of BRCA1 and BRCA2 Hum Mutat 20 02, 20 , 413– 424 180 Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T and Nagao M Germline mutations of BRCA1 in Japanese breast cancer families Cancer Res 1995, 55, 3 521 -24 181 De Leon Matsuda ML, Liede A, Kwan E, , et al BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines Int J Cancer 20 02, 98, 596-603 1 82. .. patients with germline mutations of BRCA1 Lancet 1998, 351, 316 -21 101 Osin P, Crook T, Powles T, Peto J, Gusterson B Hormone status of in- situ cancer in BRCA1 and BRCA2 mutation carriers [letter] Lancet 1998, 351, 1487 1 02 Eisinger F, Nogues C, Guinebretiere JM, et al Novel indications for BRCA1 screening using individual clinical and morphological features Int J Cancer 1999, 84, 26 3-7 103 Verhoog... Tonin PN, Begin LR, et al Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women Cancer 1997, 80, 435-41 91 Armes Jean, Matthew Egan AJ, Southey MC, et al The histological phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations Cancer 1998, 83, 23 35-45 92 Breast Cancer Linkage... in Chinese patients with early onset breast cancer and affected relatives Br J Cancer 20 00, 82, 538- 42 21 185 Ho GH, Phang BH, Ng IS, Law HY, Soo KC, Ng EH Novel germline BRCA1 mutations detected in women in Singapore who developed breast carcinoma before the age of 36 years Cancer 20 00, 89, 811-6 186 Seow A, Duffy SW, McGee MA, Lee HP Breast cancer in Singapore: trends in incidence 1968-19 92 Int J... xeroderma pigmentosum in Britain Cancer Res 1988, 48, 29 29- 32 120 Easton DF Cancer risks in AT heterozygotes Int J Radiat Biol Phys 1994, 66(6 Suppl), S177- 82 121 Easton DF The inherited component of cancer Br Med Bull 1994, 50, 22 6 122 Gatti RA, Lange E, Rotman G, et al Genetic haplotyping of ataxia-telangiectasia families localises the major gene to an ≈850 kb region on chromosome 11q23.1 Intl J Radiat Biol... detection of BRCA1 mutations by the protein truncation test Nat Genet 1995, 10, 20 8- 12 213 Plummer SJ, Anton-Culver H, Webster L, et al Detection of BRCA1 mutations by the protein truncation test Hum Mol Genet 1995, 4, 1989-93 21 4 Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Page`s S, LynchHT, Lenoir GM, Mazoyer S Screening for germline rearrangements and regulatory mutations in BRCA1 led the identification... populations and their uses for breast cancer genetics Breast Cancer Res 20 00, 2, 77–81 23 5 Moller P, Heimdal K, Apold J, et al Norwegian Inherited Ovarian Cancer Group Genetic epidemiology of BRCA1 mutations in Norway Eur J Cancer 20 01, 37, 24 28-34 23 6 Liede A, Imtiaz A, Malik A, et al Contribution of BRCA1 and BRCA2 Mutations to Breast and Ovarian Cancer in Pakistan Am J Hum Genet 20 02, 71, 595–606 23 7 Burke... Li FP, Strong LC, et al Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms Science 1990, 25 0, 123 38 138 Sidransky D, Tokino T, Helzlsouer K, et al Inherited p53 mutations in breast cancer Cancer Res 19 92, 52, 29 84-6 139 Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J P53 mutations in breast cancer Cancer Res 19 92, 52, 529 1-8 140 Lloyd KM II, Dennis... Sinilnikova OM, , et al Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated earlyonset breast and ovarian cancer Hum Mutat 20 02, 20 , 23 0 183 Tang NLS, Pang CP, Yeo W, et al Prevalence of mutations in BRCA1 gene among Chinese patients with breast cancer J Natl Cancer Inst 1999, 91, 8 82- 85 184 Sng HJ, Chang J, Feroze F, et al The prevalence of BRCA1 mutations in . Devilee P. BRCA1 and BRCA2 testing: weighing the demand against the benefits [editorial]. Am J Hum Genet 1999, 64, 943-8. 32. Foulkes WD. BRCA1 and BRCA2: penetrating the clinical arena [commentary] 351, 1487. 1 02. Eisinger F, Nogues C, Guinebretiere JM, et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer 1999, 84, 26 3-7. 103 analysis, allowing genotype/phenotype determination and predictive testing. Am J Hum Genet 1997, 33, 23 90 -2. 62. Gorski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish